Huyen Thu Nguyen

Ms. Huyen Thu Nguyen

Vinmec International Hospital, Hanoi, Hà Nội, Vietnam
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
HNHuyen Thu Nguyen
Huyen Thu Nguyen
Chau Minh DuongChau Minh Duong
Chau Minh Duong
XNXuan-Hung Nguyen
Xuan-Hung Nguyen
UTUYEN THAN
UYEN THAN
Osteoarthritis (OA) is a common degenerative disease that can lead to persistent pain and motion restriction. In the last decade, stem cells, particularly mesenchymal stem cells (MSCs), have been explored as a potential alternative OA therapy due to their regenerative capacity. Furthermore, it has been shown that trophic factors enveloped in extracellular vesicles (EVs), including exosomes, are a crucial aspect of MSC-based treatment for OA. Evidently, EVs derived from different MSC sources might rescue the OA phenotype by targeting many biological processes associated with cartilage extracellular matrix (ECM) degradation and exerting protective effects on different joint cell types. Despite this advancement, different studies employing EV treatment for OA have revealed reverse outcomes depending on the EV cargo, cell source, and pathological condition. Hence, in this review, we aim to summarize and discuss the possible effects of MSC-derived EVs based on recent findings at different stages of OA development, including effects on cartilage ECM, chondrocyte biology, osteocytes and bone homeostasis, inflammation, and pain management. Additionally, we discuss further strategies and technical advances for manipulating EVs to specifically target OA to bring the therapy closer to clinical use.

27 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DVDuc Minh Vu
Duc Minh Vu
VNVan-Tinh Nguyen
Van-Tinh Nguyen
HNHuyen Thu Nguyen
Huyen Thu Nguyen
PDPhuong Thi Xuan Do
Phuong Thi Xuan Do
HDHuy Hoang Dao
Huy Hoang Dao
UTUYEN THAN
UYEN THAN
Umbilical cord-derived mesenchymal stem cells (UCMSCs) have been illustrated for their roles in immunological modulation and tissue regeneration through the secretome. Additionally, culture conditions can trigger the secretion of extracellular vesicles (EVs) into extracellular environments with significant bioactivities. This study aims to investigate the roles of three EV sub-populations released by UCMSCs primed with transforming growth factor β (TGFβ) and their capacity to alter dermal fibroblast functions for skin aging. Results show that three EV sub-populations, including apoptotic bodies (ABs), microvesicles (MVs), and exosomes (EXs), were separated from conditioned media. These three EVs carried growth factors, such as FGF-2, HGF, and VEGF-A, and did not express noticeable effects on fibroblast proliferation and migration. Only EX from TGFβ-stimulated UCMSCs exhibited a better capacity to promote fibroblasts migrating to close scratched wounds than EX from UCMSCs cultured in the normal condition from 24 h to 52 h. Additionally, mRNA levels of ECM genes (COL I, COL III, Elastin, HAS II, and HAS III) were detected with lower levels in fibroblasts treated with EVs from normal UCMSCs or TGFβ-stimulated UCMSCs compared to EV-depleted condition. On the contrary, the protein levels of total collagen and elastin released by fibroblasts were greater in the cell groups treated with EVs compared to EV-depleted conditions; particularly elastin associated with TGFβ-stimulated UCMSCs. These data indicate the potential roles of EVs from UCMSCs in protecting skin from aging by promoting ECM protein production.

14 November 2023 in Heliyon
Verified
Journal Article
Open access
MLMai Thi Le
Mai Thi Le
HNHuyen Thu Nguyen
Huyen Thu Nguyen
XNXuan-Hung Nguyen
Xuan-Hung Nguyen
HDHai Xuan Do
Hai Xuan Do
BMBinh Thanh Mai
Binh Thanh Mai
TNThanh-Hong Nguyen
Thanh-Hong Nguyen
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%–85% of total cases and leading to millions of deaths worldwide. Drug resistance is the primary cause of treatment failure in NSCLC, which urges scientists to develop advanced approaches for NSCLC treatment. Among novel approaches, the miRNA-based method has emerged as a potential approach as it allows researchers to modulate target gene expression. Subsequently, cell behaviors are altered, which leads to the death and the depletion of cancer cells. It has been reported that miRNAs possess the capacity to regulate multiple genes that are involved in various signaling pathways, including the phosphoinositide 3-kinase, receptor tyrosine kinase/rat sarcoma virus/mitogen-activated protein kinase, wingless/integrated, retinoblastoma, p53, transforming growth factor β, and nuclear factor-kappa B pathways. Dysregulation of these signaling pathways in NSCLC results in abnormal cell proliferation, tissue invasion, and drug resistance while inhibiting apoptosis. Thus, understanding the roles of miRNAs in regulating these signaling pathways may enable the development of novel NSCLC treatment therapies. However, a comprehensive review of potential miRNAs in NSCLC treatment has been lacking. Therefore, this review aims to fill the gap by summarizing the up-to-date information on miRNAs regarding their targets, impact on cancer-associated pathways, and prospective outcomes in treating NSCLC. We also discuss current technologies for delivering miRNAs to the target cells, including virus-based, non-viral, and emerging extracellular vesicle-based delivery systems. This knowledge will support future studies to develop an innovative miRNA-based therapy and select a suitable carrier to treat NSCLC effectively.

14 November 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HDHuy Hoang Dao
Huy Hoang Dao
HNHuyen Thu Nguyen
Huyen Thu Nguyen
DHDiem Huong Hoang
Diem Huong Hoang
BVBach Duong Vu
Bach Duong Vu
MTMinh-Anh Tran
Minh-Anh Tran
XNXuan-Hung Nguyen
Xuan-Hung Nguyen
Mesenchymal stem cell (MSC)-derived exosomes (EXs) have emerged as promising therapeutic agents for wound healing. However, the optimal conditions for manufacturing MSC-derived EXs that maximize their wound-healing potential have yet to be established. Hence, we compared the efficacy of five different MSC culture media, including three different serum-free, a platelet-supplemented, and a fetal bovine serum-supplemented media, in exosome manufacturing for wound healing applications. Although umbilical cord-derived MSCs (UCMSCs) cultured in these media exhibited similar proliferation, morphology, MSC surface marker expression, and stemness, EXs derived from UCMSCs cultured in different culture media displayed varying levels of growth factors and cytokines. Notably, EXs derived from platelet-supplemented media (DM-PLT_EXs) exhibited significantly higher concentrations of keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF-A), platelet-derived growth factor (PDGF-BB), interleukin 6 (IL-6), interleukin 7 (IL-7), and interleukin 8 (IL-8) than EXs from other media. These differences correlated with the superior capability of DM-PLT_EXs to promote human skin fibroblast proliferation and stimulate angiogenesis of human umbilical vein endothelial cells, making them a more suitable choice for wound healing applications. Our findings emphasize the significance of the culture medium selection in tailoring the therapeutic potential of UCMSC-derived EXs for wound healing.

1 May 2023 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
XDXuan-Hai Do
Xuan-Hai Do
MLMai Thi Le
Mai Thi Le
HNHuyen Thu Nguyen
Huyen Thu Nguyen
TLThanh Thien Le
Thanh Thien Le
XNXuan-Hung Nguyen
Xuan-Hung Nguyen
UTUYEN THAN
UYEN THAN
Purpose: Hepatocellular carcinoma (HCC), a prevalent type of liver cancer, is mainly diagnosed in the advanced stage, leading to a high mortality rate. Recent advances have identified peripheral cytokines as a potential tool to predict disease outcomes and inform therapeutic decisions. Hence, in this study, we aim to build a predictive model for HCC based on serum levels of different cytokines. Patients and Methods: We used immunoassay to quantify the concentrations of IL-27, MIP-1β, Perforin, sCD137, sFas, and TNF-α in the serum of 38 HCC patients and 15 healthy controls. Logistic regression was then used to construct classification models detecting HCC based on these cytokines. A nomogram of the best-performing model was generated to visualize HCC prediction. Results: sFas and MIP-1β were found to be significantly higher in HCC patients compared to controls. Predictive models based on cytokine levels combining sFas, sCD137, and IL-27 performed the best in distinguishing HCC patients from healthy controls. This model has a bias-corrected area under the receiver operating characteristic (ROC) curve (AUC) of 0.948, a sensitivity of 92.11%, a specificity of 93.33%, and an accuracy of 0.925. Conclusion: Our findings suggest that serum cytokines have the potential to be utilized in HCC screening to improve detection rates.

5 May 2026 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
PVPetra Vrdoljak
Petra Vrdoljak
AIAlessandro Idrovo‐Gavilanes
Alessandro Idrovo‐Gavilanes
HNHuyen Thu Nguyen
Huyen Thu Nguyen
ACAmélie Vander Cruyssen
Amélie Vander Cruyssen
NGNiké Guilbert
Niké Guilbert
AHAn Hendrix
An Hendrix
The widespread use of fluorescent dyes for extracellular vesicle (EV) labeling has substantially improved our ability to trace EVs in vitro , ex vivo , and in vivo . However, interpretability of these experiments remains limited by methodological challenges, including incomplete dye removal, dye‐associated artifacts, and intrinsic EV heterogeneity. In this study, we evaluated a range of mechanistically distinct fluorescent dyes, including lipophilic membrane‐ (Aco‐520, DiD, FM4‐64, PKH26) and protein‐associated dyes (CFSE, Cy5), across EVs of both prokaryotic and eukaryotic origin. EV labeling was assessed at the single‐vesicle level by nano‐flow cytometry, complemented by super‐resolution microscopy for visual confirmation. Our results demonstrated that EV labeling efficiency, fluorescence intensity, and background signal are not solely determined by dye chemistry but are also strongly influenced by EV biological origins. Furthermore, free dye removal and purification strategies markedly influenced nano‐flow cytometry readouts, underscoring the need to utilize and optimize approaches such as ultracentrifugation and size‐exclusion chromatography to effectively remove residual dye while minimizing EV loss and artifactual signals. Across all conditions, appropriate controls were critical to distinguish bona fide EV‐associated fluorescence from artifactual events. Overall, our findings reinforce that no single dye is universally suitable for EV labeling and underscore the necessity of a question‐driven, context‐aware experimental design. We therefore include a box with key questions to support informed decision‐making and improve rigor in EV labeling workflows. Addressing these guiding questions prior to experimentation, together with transparent reporting in platforms such as EV‐TRACK will improve reproducibility, data interpretation, and the robustness of EV research.